The investigators propose to carry out a single blinded randomized controlled trial where 33 patients will receive midazolam and ketamine for sedation in one arm and 33 will receive the standard fentanyl and midazolam combination in the other arm. During the procedure, the investigators will measure and record vital signs as well as the total dose of medication used. After the procedure, the investigator will note the time to recovery and discharge. The bronchoscopist will be asked to assess the quality of the procedure as well as a checklist to the patient to be done immediately after the procedure and 48 hours post procedure.

A patient presents to the pulmonary clinic for a scheduled outpatient bronchoscopy. During the initial visit to discuss the need for bronchoscopy, patients will be provided with a brochure on the study and advised that if they meet inclusion criteria, they may elect to participate. If the patient elects to participate in the study and meets inclusion and exclusion criteria they will be consented and enrolled. Once enrolled, the study personnel will then retrieve the subject's assigned envelope that will contain all the data collection forms and the study medication will be ordered. If the patient is enrolled in the ketamine arm, an order for ketamine will be placed in in the electronic medical record to the inpatient OR pharmacy for 10mg/ml (10ml) prefilled syringe. Pulmonary clinic nursing personnel will pick up the ketamine syringe from inpatient OR pharmacy. In the Bronchoscopy Suite, nurse will affix a sticker "Drug A" to cover the ketamine 10mg/mL pharmacy label. The remainder of the medications will be pulled from the pyxis machine in the bronchoscopy suite and kept on standby by the bedside nurse.

Once consented, the nurse or physician taking care of the patient will then take the sealed envelope within the packet containing the subject's randomized medication assignment and give this sealed envelope to the nurse involved in the subject's care to retrieve the medication. To maintain the study protocol the ketamine syringe will be labeled as 'drug A" The bedside nurse will label the syringe with midazolam and fentanyl as "drug B and drug C" respectively along with the amount, the patient name and the initial of the preparer, then give the medications to the attending physician for verification and administration by either the attending physician or fellow physician under direct supervision of the attending physician. The patient will be blinded to the study medication but the physicians and nursing staff will know the identity of the medications being administered. The subject will continue on with care as directed by the provider. There will be at least two licensed providers in the room for the duration of the procedure.

In regards to quality of sedation, procedural sedation will be titrated to achieve a RASS score of negative 1 to negative 3. In the patient's randomized to the ketamine arm they will receive an initial 1mg dose of IV midazolam for anxiolysis followed by Ketamine at an initial dose of 0.25 - 0.5 mg/kg administered over 1 minute. Additional doses of ketamine 10-20mg will be administered every 5-10 minutes until an appropriate level of sedation is achieved. Additional midazolam can be given for anxiety at the discretion of the attending physician. If the procedure calls for fentanyl to be used instead of ketamine, midazolam will be given in 1mg and fentanyl in 25mcg increments every 3 minutes and titrated to achieve a RASS of -3. During the procedure, the physician and nursing staff will refer to ketamine as "A" and then the dose (e.g. "please administer 10 mg of A") and midazolam as "B" in order to prevent the subject from knowing the identity of the study medication. If the bronchoscopist does not feel adequate sedation has been achieved after several doses of ketamine (at least 4 doses), they may convert the procedure to standard sedation consisting of fentanyl and midazolam and drop the subject from the study. Additionally, if the procedure is started and it is determined that the patient cannot be adequately sedated then the physician can elect to abort the procedure and drop the subject from the study. After completion of the procedure, the bronchoscopist will be given a form in which to rate the quality of procedural sedation; attached for review. During the procedure, vital signs and medication dose administration data will be recorded on the medication use sheet as already used in the BAMC pulmonary suite. Following the procedure, all immediate complications during the procedure will be recorded.

The investigator will record the time elapsed from medication administration until discharge from the recovery area. Subjects will be discharged from the recovery area after they meet preset parameters found in the standard operating procedures of the bronchoscopy suite. Procedural times such start time, completion of procedure, and total dose of sedation will be documented in the procedural report as currently preformed for all bronchoscopies. The total dose of sedation will be added to the procedural report by a study team member after the physician has filled out the report and submitted their sedation checklists as detailed below in order to maintain proper blinding. Immediately following the procedure, the bronchoscopist will complete a form rating: the overall quality of sedation, rating of subject discomfort, sedation-related technical difficulties, and depth of sedation. It will also me noted on the data recording form if the patient has an active prescription for opioids, benzodiazepines, or if they consume greater than or equal to five alcohol drinks per week.

After the subject meets the preset parameters found in the standard operating procedures of the bronchoscopy suite for discharge, a post-procedural checklists will be administered and the subject will be discharged home. The subject will be contacted via phone 48 hours after the procedure and will be asked to rate the quality of the procedure via the modified PSSI index as well as additional questions about their oral intake and if they experienced any side effects specific to ketamine. A sample of the script for the post-procedural phone call will be attached for review. The investigator will attempt to contact each subject at least 3x starting 48 hours after the procedure for two more days. voicemails will be left after each attempt. If they are unreachable, they will then be noted as lost to follow up.

All checklists will be sealed into separate envelopes and will be placed in the subject's overall study envelope. The envelopes will remain sealed until the study results are analyzed.